ProQR(PRQR) - 2024 Q4 - Annual Report

Financial Reporting and Compliance - The financial statements have been prepared in accordance with IFRS, requiring estimates and assumptions that may differ from actual results[538] - There have been no material adjustments to prior period estimates for any of the periods included in the Annual Report[538] - The Company uses non-GAAP financial measures alongside IFRS measures to present its financial position and operating results[24] - The Company maintains its books and records in euro, presenting financial statements in this currency as its functional currency[25] Risks and Uncertainties - Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from expectations[32] - The Company faces risks related to geopolitical developments, including economic sanctions and trade barriers that could impact operations[37] - The impact of health epidemics and global supply chain pressures may slow or halt operations and activities[37] - The Company has not made any updates to forward-looking statements after the date of the Annual Report[36] Clinical Trials and Collaborations - The Company relies on contract research organizations (CROs) for timely enrollment in clinical trials, which may affect execution timelines[33] - The collaboration with Eli Lilly and Company includes potential milestone and royalty payments from commercial product sales[33]